



Brief report

Baseline immunity to diphtheria and immunologic response after booster vaccination with reduced diphtheria and tetanus toxoid vaccine in Thai health care workers



Surasak Wiboonchutikul MD^{a,*}, Weerawat Manosuthi MD^a, Chariya Sangsajja MD^a,
Varaporn Thientong RN^a, Sirirat Likanonsakul MSc^a, Somkid Srisopha BSc^a,
Patamavadee Termvises RN^a, Jitlada Rujitip RN^a, Suda Loiusirirotchanakul PhD^b,
Pilaipan Puthavathana PhD^b

^a Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

^b Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Key Words:

Diphtheria antibody
Serologic response
Health care personnel
Booster immunization
Thailand

A prospective study to evaluate immune status against diphtheria and immunologic response after tetanus-diphtheria (Td) booster vaccination was conducted in 250 Thai health care workers (HCWs). A protective antibody was found in 89.2% of the HCWs (95% confidence interval [CI], 83.3%–91.5%) before receipt of the Td booster vaccination, compared with 97.2% (95% CI, 95.1%–99.3%) after receipt of the first dose of booster ($P < .001$). The mean antibody level against diphtheria increased from 0.39 IU/mL (95% CI, 0.35–0.44 IU/mL) before the Td booster vaccination to 1.20 IU/mL (95% CI, 1.12–1.29 IU/mL) after the vaccination ($P < .001$). Td booster vaccination should be considered for Thai HCWs to maintain immunity against diphtheria, which still circulates in Thailand.

Copyright © 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. All rights reserved.

Health care workers (HCWs) are at risk of acquiring communicable diseases from their patients. Diphtheria is one of the fatal communicable diseases circulating in many countries, including Thailand.¹ Numerous studies have reported declining immune protection against diphtheria with increasing age.^{2–5} Data on immune status against diphtheria among HCWs in countries with a high prevalence of diphtheria are lacking. In the present study, we assessed immunity to diphtheria among Thai HCWs and examined factors associated with immune protection against diphtheria. We also evaluated the immunologic response to and safety of the tetanus-diphtheria toxoid (Td) booster vaccination.

METHODS

Study design

This prospective study was conducted between March and September 2013 at Bamrasnaradura Infectious Diseases Institute in

* Address correspondence to Surasak Wiboonchutikul, MD, Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand.

E-mail address: srsw135@yahoo.com (S. Wiboonchutikul).

This work was supported by the Department of Disease Control, Ministry of Public Health, Thailand.

Conflict of interest: None to report.

Nonthaburi, Thailand. Participants were HCWs aged 18–60 years who were willing to participate and provided written informed consent. HCWs who were allergic to Td or tetanus toxoid (TT) or who had received Td within 3 years before enrollment were excluded. Demographic data were collected using a questionnaire. Blood samples were collected before and after Td booster vaccination. The level of antibody against diphtheria toxoid was measured by indirect enzyme-linked immunosorbent assay using a commercial kit (Euroimmun Medizinische Labordiagnostika, Lubeck, Germany). A diphtheria antibody level ≥ 0.1 IU/mL was considered sufficient to provide seroprotection. A 0.5-mL dose of Td vaccine (Serum Institute of India, Pune, India) containing 5 Lf units of diphtheria toxoid and 5 Lf units of TT with 1.25 mg of aluminium phosphate was injected intramuscularly after baseline blood collection and again 6 weeks later to those who demonstrated no seroprotection. Participants who had received the Td booster within 3–5 years before enrollment were assigned to wait for their immunity results, and were not vaccinated if immunity was established. Participants were observed directly for immediate adverse events, and were contacted by telephone at 14 days after vaccination to check for any later adverse events.

This study was approved by the Ethics Committee for Research in Human Subjects of the Department of Disease Control, Thailand Ministry of Public Health.

Table 1
Baseline characteristics of study participants

Characteristic	All (n = 250)	Immune (n = 223)	Nonimmune (n = 27)	P value
Sex, n (%)				.153
Male	59 (23.6)	50 (22.4)	9 (33.3)	
Female	191 (76.4)	173 (77.6)	18 (66.7)	
Age, y, mean (SD)	35.4 (11.7)	35.2 (11.9)	37.9 (9.9)	.363
Year of birth, n (%)				.482
Before 1977	110 (44.0)	97 (43.5)	13 (48.1)	
1977-1981*	30 (12.8)	27 (12.1)	5 (18.5)	
1982-1991*	82 (32.0)	72 (32.3)	8 (29.6)	
After 1991*	28 (11.2)	27 (12.1)	1 (3.7)	
Body mass index, mean (SD)	23.4 (5.6)	23.7 (5.5)	24.4 (6.2)	.525
Staff position, n (%)				.579
Clinical	155 (62.0)	137 (61.4)	18 (66.7)	
Nonclinical ancillary	87 (34.8)	78 (35.0)	9 (33.3)	
Laboratory	8 (3.2)	8 (3.6)	0	
Home town, n (%)				.368
Bangkok	37 (14.8)	32 (14.3)	5 (18.5)	
Province	213 (85.2)	191 (85.7)	22 (81.5)	
Primary school, n (%)				.616
Bangkok	29 (11.6)	26 (11.7)	3 (11.1)	
Province	221 (88.4)	197 (88.3)	24 (88.9)	
History of childhood vaccination, n (%)				.030
Complete	100 (40.0)	86 (38.6)	14 (51.9)	
Incomplete	5 (2.0)	3 (1.3)	2 (7.4)	
Unknown	145 (58.0)	134 (60.1)	11 (40.7)	
History of diphtheria infection, n (%)				.795
Yes	2 (0.8)	2 (0.9)	0	
No	248 (99.2)	221 (99.1)	27 (100)	
History of close contact with patients with diphtheria, n (%)				.605
Yes	8 (3.2)	7 (3.1)	1 (3.7)	
No	242 (96.8)	216 (96.9)	26 (96.3)	
Adult booster with TT or Td vaccine, n (%)				.539
Yes	183 (73.2)	163 (73.1)	20 (74.1)	
No or unknown	67 (26.8)	60 (26.9)	7 (25.9)	
Type of vaccine, n/N (%) [‡]				.096
TT	119/183 (65.0)	104/164 (64.2)	15/19 (78.9)	
Td	55/183 (30.1)	53/164 (32.7)	2/19 (10.5)	
Not sure	9/183 (4.9)	7/164 (3.1)	2/19 (10.5)	
Time from last booster to enrollment, n/N (%) [‡]				.372
3-5 y	36/183 (19.7)	32/164 (19.5)	4/19 (21.1)	
6-10 y	37/183 (20.2)	34/164 (20.7)	3/19 (15.8)	
>10 y	25/183 (13.7)	20/164 (12.2)	5/19 (26.3)	
Unknown	85/183 (46.4)	78/164 (47.6)	7/19 (36.8)	

*1977: year of implementation of the first routine infant immunization program with 2 doses of diphtheria and tetanus toxoids, and whole-cell pertussis (DTP) vaccine for all Thai infants. In 1982, the recommendation was changed to 3 doses of DTP vaccine, and in 1992 it was modified to 5 doses of DTP at age 2, 4, 6, and 18 months and 4-6 years.

[†]Clinical staff: those who had regular contact with patients; nonclinical ancillary staff: those who may have had social contact with patients.

[‡]One hundred and eighty-three HCWs had a history of adult booster with the TT or Td vaccine before enrollment.

Data analysis

The Pearson correlation coefficient (*r*) was used to evaluate the correlation between age and diphtheria antibody levels. Mean antibody levels and rates of seroprotection to diphtheria before and after the first Td booster vaccination were compared using the paired *t* test and χ^2 test, respectively. Variables with a *P* < .10 in univariate analysis were included in multiple logistic regression models to identify factors associated with immune protection to diphtheria at baseline. All statistical analyses were performed with SPSS version 15.0 (SPSS, Chicago, IL).

RESULTS

Baseline characteristics of the 250 HCWs participating in this study are shown in Table 1. The correlation (*r*) between age and baseline diphtheria antibody level was 0.14 (*P* = .024) (Fig 1). Seroprotection was detected in 89.2% of the HCWs before receipt of the Td booster immunization, compared with 97.2% after receipt of the first Td booster dose (*P* < .001). The mean antibody level against diphtheria was 0.39 IU/mL (95% confidence interval [CI], 0.35-0.44

IU/mL) before immunization and 1.20 IU/mL (95% CI, 1.12-1.29 IU/mL) after the first booster dose (*P* < .001). Among immune HCWs, 9.9% had an antibody level >1 IU/mL at enrollment, which increased to 65.2% after receipt of the Td booster (*P* = .015).

For exploring the factors associated with immune protection to diphtheria at baseline, among the variables listed in Table 1, only a history of incomplete childhood vaccination (odds ratio [OR], 0.12; 95% CI, 0.02-0.82) and a history of receipt of the adult Td booster vaccination (OR, 10.6; 95% CI, 1.22-92.27) had a *P* value < .10 in univariate analysis. In multivariate analysis, only a history of receipt of the adult Td booster vaccination was a significant associated factor (OR, 5.39; 95% CI, 1.08-26.80; *P* = .040). Pain at the injection site was the most frequently reported local adverse effect of the Td vaccine, and myalgia was the most common systemic adverse effect. No serious adverse events were observed.

DISCUSSION

Our results demonstrate that Thai HCWs may be at risk of acquiring diphtheria infection. Compared with other studies of




Fig 1. Antibody levels against diphtheria by age at baseline measurement (n = 250).

HCWs, in this study, the prevalence of HCWs with immunity against diphtheria was higher than that reported in Spain,⁶ but comparable to that in a study from Brazil.⁷ Using a diphtheria antibody titer ≥ 0.1 IU/mL as a seroprotective level and studying the same age group, we found a higher seroprotection rate at baseline compared with a previous study in Thailand⁸ (89.0% vs 53.9%). Our higher rate could have resulted from implementation of the national Extended Program on Immunization (EPI) for infants and children in 1977. Nonetheless, most participants born before institution of EPI who were not receiving routine Td booster vaccinations also had immune protection. Considering the high prevalence of diphtheria infection in the past 20–30 years in Thailand,¹ repeated natural boosters from the environment could have affected long-term immunity.^{9,10} The combination of immunity from vaccination and natural contact with circulating diphtheria in the past might have contributed to our findings in our study. It also may explain why we found a poor correlation between age and diphtheria immunity level. This latter result conflicts with numerous previous studies performed in countries with a low prevalence of diphtheria, which have shown declining immunity level with increasing age.^{2–5} With the current reduction of diphtheria incidence, it should be emphasized that 90.1% of our immune participants had an antibody level between 0.1 and 1.0 IU/mL at enrollment, which may provide protection against diphtheria for a few years if immunity was acquired by childhood immunization.¹⁰ Our results clearly suggest that the recommended immunization

schedule for Thai HCWs should be changed from a booster with TT or Td¹¹ to Td only, given every 10 years.

This study has some limitations, including the small sample size, use of local data only, and single-center nature, which may limit the generalizability of our findings. A number of the participants reported frequent changes in workplace, preventing categorization of some key epidemiologic data, wards worked in and duration of work, for analysis.

In summary, Thai HCWs may be at risk of acquiring diphtheria infection. The Td vaccine is safe, and the booster vaccination should be recommended for Thai HCWs. A routine Td booster vaccination program in Thai HCWs should be considered by local and public health administrators.

Acknowledgments

The authors thank Uthaiwan Singkham and Sakaphon Rungroj for their assistance with data collection, Jarunee Prasertsophon and Duangjai Oddgun for their assistance with laboratory work, Chinda Kanoksinsombat for study coordination, and Suthat Chottanapund, MD, PhD for statistical advice.

References

1. World Health Organization. WHO vaccine-preventable diseases: monitoring system, 2013 global summary. Available from: http://apps.who.int/immunization_monitoring/globalsummary. Accessed December 18, 2013.
2. Jenum PA, Skogen V, Danilova E, Eskild A, Sjurson H. Immunity to diphtheria in northern Norway and northwestern Russia. *Eur J Clin Microbiol Infect Dis* 1995;14:794–8.
3. McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. *Ann Intern Med* 2002;136:660–6.
4. Nakajima H, Kariya H, Ohata R, Ogura H. Investigation of immunity level against diphtheria and reinforcement of immunity by booster vaccination for infection control staff in Okayama prefecture. *Jpn J Infect Dis* 2008;61:104–6.
5. Tansel O, Ekuclu G, Eker A, Kunduracilar H, Yulugkural Z, Yuksel P. Community-based seroepidemiology of diphtheria and tetanus in Edirne, Turkey. *Jpn J Infect Dis* 2009;62:275–8.
6. Esteve M, Dominguez A, Urbiztondo L, Borrás E, Costa J, Broner S, et al. Prevalence of susceptibility to tetanus and diphtheria in health care workers in Catalonia. *Am J Infect Control* 2012;40:896–8.
7. dos Santos AM, Ono E, Lobato RT, do Prado SI, Kopelman BI, Cavalcanti CM, et al. Diphtheria, tetanus, and varicella immunity in health care workers in neonatal units. *Am J Infect Control* 2008;36:142–7.
8. Tharmaphornpilas P, Yoocharoan P, Prempre P, Youngpairoj S, Sriprasert P, Vitek CR. Diphtheria in Thailand in the 1990s. *J Infect Dis* 2001;184:1035–40.
9. Hasselhorn HM, Nubling M, Tiller FW, Hofmann F. Factors influencing immunity against diphtheria in adults. *Vaccine* 1998;16:70–5.
10. Galazka A. The changing epidemiology of diphtheria in the vaccine era. *J Infect Dis* 2000;181(Suppl 1):S2–9.
11. Royal College of Physicians of Thailand. Recommended adult and elderly immunization schedule, 2011. Available from: <http://www.rcpt.org/index.php/news/2012-09-24-09-26-20.html>. Accessed January 21, 2014.